Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Positive regulation of raphe serotonin neurons by serotonin 2B receptors.

Belmer A, Quentin E, Diaz SL, Guiard BP, Fernandez SP, Doly S, Banas SM, Pitychoutis PM, Moutkine I, Muzerelle A, Tchenio A, Roumier A, Mameli M, Maroteaux L.

Neuropsychopharmacology. 2018 Jun;43(7):1623-1632. doi: 10.1038/s41386-018-0013-0. Epub 2018 Feb 5.

PMID:
29453444
2.

Differential alteration of hippocampal function and plasticity in females and males of the APPxPS1 mouse model of Alzheimer's disease.

Richetin K, Petsophonsakul P, Roybon L, Guiard BP, Rampon C.

Neurobiol Aging. 2017 Sep;57:220-231. doi: 10.1016/j.neurobiolaging.2017.05.025. Epub 2017 Jun 6.

PMID:
28666707
3.

Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers.

Moutkine I, Quentin E, Guiard BP, Maroteaux L, Doly S.

J Biol Chem. 2017 Apr 14;292(15):6352-6368. doi: 10.1074/jbc.M117.779041. Epub 2017 Mar 3.

4.

Serotonin Signaling through Prefrontal Cortex 5-HT1A Receptors during Adolescence Can Determine Baseline Mood-Related Behaviors.

Garcia-Garcia AL, Meng Q, Canetta S, Gardier AM, Guiard BP, Kellendonk C, Dranovsky A, Leonardo ED.

Cell Rep. 2017 Jan 31;18(5):1144-1156. doi: 10.1016/j.celrep.2017.01.021.

5.

Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.

Qesseveur G, Petit AC, Nguyen HT, Dahan L, Colle R, Rotenberg S, Seif I, Robert P, David D, Guilloux JP, Gardier AM, Verstuyft C, Becquemont L, Corruble E, Guiard BP.

Neuropharmacology. 2016 Jun;105:142-153. doi: 10.1016/j.neuropharm.2015.12.022. Epub 2016 Jan 4.

PMID:
26764241
6.

Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice.

Quesseveur G, Portal B, Basile JA, Ezan P, Mathou A, Halley H, Leloup C, Fioramonti X, Déglon N, Giaume C, Rampon C, Guiard BP.

Front Cell Neurosci. 2015 Dec 22;9:490. doi: 10.3389/fncel.2015.00490. eCollection 2015.

7.

High-fat diet-induced metabolic disorders impairs 5-HT function and anxiety-like behavior in mice.

Zemdegs J, Quesseveur G, Jarriault D, Pénicaud L, Fioramonti X, Guiard BP.

Br J Pharmacol. 2016 Jul;173(13):2095-110. doi: 10.1111/bph.13343. Epub 2015 Dec 9.

8.

Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?

Guiard BP, Di Giovanni G.

Front Pharmacol. 2015 Mar 17;6:46. doi: 10.3389/fphar.2015.00046. eCollection 2015. Review.

9.

Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder.

Petit AC, Quesseveur G, Gressier F, Colle R, David DJ, Gardier AM, Ferreri F, Lépine JP, Falissard B, Verstuyft C, Guiard BP, Corruble E.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:76-82. doi: 10.1016/j.pnpbp.2014.04.013. Epub 2014 May 5.

PMID:
24801750
10.

The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.

Quesseveur G, Gardier AM, Guiard BP.

Curr Drug Targets. 2013 Oct;14(11):1277-94. Review.

PMID:
24020973
11.

Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.

Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ.

Neuropharmacology. 2013 Oct;73:147-59. doi: 10.1016/j.neuropharm.2013.05.014. Epub 2013 May 28.

12.

5-HT2 ligands in the treatment of anxiety and depression.

Quesseveur G, Nguyen HT, Gardier AM, Guiard BP.

Expert Opin Investig Drugs. 2012 Nov;21(11):1701-25. doi: 10.1517/13543784.2012.719872. Epub 2012 Aug 24. Review.

PMID:
22917059
13.

Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression.

Hache G, Guiard BP, Le Dantec Y, Orvoën S, David DJ, Gardier AM, Coudoré F.

Neuroreport. 2012 Jun 20;23(9):525-9. doi: 10.1097/WNR.0b013e328353d70a.

PMID:
22555563
14.

Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.

Nguyen HT, Guiard BP, Bacq A, David DJ, David I, Quesseveur G, Gautron S, Sanchez C, Gardier AM.

Br J Pharmacol. 2013 Jan;168(1):103-16. doi: 10.1111/j.1476-5381.2012.01850.x.

15.

Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration.

Rainer Q, Nguyen HT, Quesseveur G, Gardier AM, David DJ, Guiard BP.

Mol Pharmacol. 2012 Feb;81(2):106-12. doi: 10.1124/mol.111.075796. Epub 2011 Oct 26.

16.

Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety.

Richardson-Jones JW, Craige CP, Nguyen TH, Kung HF, Gardier AM, Dranovsky A, David DJ, Guiard BP, Beck SG, Hen R, Leonardo ED.

J Neurosci. 2011 Apr 20;31(16):6008-18. doi: 10.1523/JNEUROSCI.5836-10.2011.

17.

Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study.

Guiard BP, Mansari ME, Murphy DL, Blier P.

Int J Neuropsychopharmacol. 2012 Apr;15(3):349-61. doi: 10.1017/S1461145711000484. Epub 2011 Mar 25.

PMID:
21439106
18.

Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments.

Guilloux JP, David DJ, Xia L, Nguyen HT, Rainer Q, Guiard BP, Repérant C, Deltheil T, Toth M, Hen R, Gardier AM.

Neuropharmacology. 2011 Sep;61(3):478-88. doi: 10.1016/j.neuropharm.2011.02.009. Epub 2011 Feb 17.

PMID:
21333660
19.

Glucocorticoid receptors in dopaminoceptive neurons, key for cocaine, are dispensable for molecular and behavioral morphine responses.

Barik J, Parnaudeau S, Saint Amaux AL, Guiard BP, Golib Dzib JF, Bocquet O, Bailly A, Benecke A, Tronche F.

Biol Psychiatry. 2010 Aug 1;68(3):231-9. doi: 10.1016/j.biopsych.2010.03.037. Epub 2010 Jun 15.

PMID:
20554270
20.

Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder.

El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P.

CNS Neurosci Ther. 2010 Jun;16(3):e1-17. doi: 10.1111/j.1755-5949.2010.00146.x. Epub 2010 Apr 8. Review.

Supplemental Content

Loading ...
Support Center